<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200510047380N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-01-29</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>The effect of ischemic preconditioning in patients with acute Myocardial infraction</public_title>
      <acronym></acronym>
      <scientific_title>A study on effects of ischemic preconditioning on the occurrence rate of major cardiovascular complications in patients suffering from acute myocardial infraction with ST segment elevation</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>160</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/60309</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: According to the estimated sample size, 80 patients in the intervention group and 80 patients in the control group based on consecutive sampling and having inclusion criteria based on four random blocks whose sequence by Sealed Envelope software Ltd.2021.Created a block Randomisation list {Online} Available from: https://www.sealedenvelope.com/simple -randomiser / v1 / lists {Accessed 13 Sep 2021}
The list is kept inside a sealed letter at the Healthy Heart Research Center. After permission to conduct the study, patients are assigned to the intervention and control groups on a daily basis. It should be noted that this sequence list consists of 40 quadruple random blocks. This study is a single-blind clinical trial study. The method of blinding in the study will be that the intervention of patients by one of the assistants and the evaluation of complications and measurement of left ventricular ejection fraction by another assistant. Patients have no information about the type of intervention, Blinding description: This study is a single-blind clinical trial. the independent variable in this study is the intervention group against control group, the outcomes of this study(heart failure, recurring myocardial infraction, stroke and death) are the primary end points , and ejection fraction(EF) is the secondary end point.</study_design>
      <phase>N/A</phase>
      <hc_freetext>ST segment elevation acute myocardial infraction.</hc_freetext>
      <i_freetext>Intervention 1: Patients with acute myocardial infarction with ST-segment elevation who are candidates for Primary PCI and undergo RIC. The cuff is placed on one of the upper limbs and inflated to 30 mm/hg higher than systolic pressure for a period of 5  minutes. The process is repeated 3 times with a 5-minute interval. Intervention 2: Control group: Patients with acute myocardial infarction with ST-segment elevation who were candidates for Primary PCI.  The cuff is placed on one of the upper limbs and inflated to 30 mm/hg higher than systolic pressure for a period of 5  minutes. The process is repeated 3 times with a 5-minute interval.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after unidentified individuals.

When:
Access period 6 months after printing the results

To whom:
Researchers working in academic and scientific institutions

Conditions:
In order to conduct further research at the written request of the Scientific Institute.

Where to obtain:
applicants for receiving documents and data can refer to the Healthy Heart Research Center located in Heshmat Hospital. They can also call 01333664282.

How to obtain:
The applicant can refer to the Healthy Heart Research Center after receiving  Confirmation from the project manager, the documents and data will be available to him within a week.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyyed Aboozar Fakhr Mousavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dr Heshmat Hospital, Mosalla square</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4193955588</zip>
        <telephone>+98 13 3366 3070</telephone>
        <email>aboozar-fm@yahoo.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyyed Aboozar Fakhr Mousavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dr Heshmat Hospital, Mosalla square</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4193955588</zip>
        <telephone>+98 13 3366 3070</telephone>
        <email>aboozar-fm@yahoo.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients over 18 coming into the emergency room because of chest pain that has started less tan 12 hours before
ECG shows ST elevation equaling or higher than 0/1 mill volt in two parallel leads(ST elevation equals or is higher than 0/2 mill volt in v1 to v3 leads)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients in cardiogenic shock
Patients who die before or immediately after percutaneous coronary intervention(PCI)
Patients with a history of myocardial infarction or coronary artery bypass graft
12 hours or more have elapsed since the onset of maximal chest pain</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I24.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acute ischemic heart disease, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Patients with acute myocardial infarction with ST-segment elevation who are candidates for Primary PCI and undergo RIC. The cuff is placed on one of the upper limbs and inflated to 30 mm/hg higher than systolic pressure for a period of 5  minutes. The process is repeated 3 times with a 5-minute interval.</i_keyword>
      <i_keyword>Control group: Patients with acute myocardial infarction with ST-segment elevation who were candidates for Primary PCI.  The cuff is placed on one of the upper limbs and inflated to 30 mm/hg higher than systolic pressure for a period of 5  minutes. The process is repeated 3 times with a 5-minute interval.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Patients with acute ST-segment elevation myocardial infarction. Timepoint: Before the intervention and 3 months later and 6 months after acute myocardial infarction. Method of measurement: Based on electrocardiogram tape.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Heart failure, recurrent myocardial infarction, stroke and death, left ventricular ejection fraction. Timepoint: Before the intervention, 3 months later and 6 months later. Method of measurement: Through a researcher-made questionnaire and echocardiography device.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rasht University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-09-29</approval_date>
        <contact_name>Research Ethics Committees of Guilan university of  medical sciences</contact_name>
        <contact_address>Dr Heshmat Hospital, mosalla Square, Rasht, Guilan Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
